| Steven Scholl, Dpm | |
|
20 Continental Ave, 1h, Forest Hills, NY 11375-5266 | |
| (718) 268-0660 | |
| Not Available |
| Full Name | Steven Scholl, Dpm |
|---|---|
| Type | Facility |
| Speciality | Durable Medical Equipment & Medical Supplies |
| Location | 20 Continental Ave, Forest Hills, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548443880 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | (New York) | Secondary |
| 332B00000X | Durable Medical Equipment & Medical Supplies | 5347190001 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Steven Scholl, Dpm 20 Continental Ave, 1h, Forest Hills, NY 11375-5266 Ph: (718) 268-0660 | Steven Scholl, Dpm 20 Continental Ave, 1h, Forest Hills, NY 11375-5266 Ph: (718) 268-0660 |
News Archive
British and Austrian scientists receive award for basic neurological research. Alastair Compston and Hans Lassmann are this year's recipients of the K. J. Zülch Prize for basic neurological research. In bestowing this award, the Gertrud Reemtsma Foundation is honouring two scientists who have made crucial contributions to research on multiple sclerosis. Alastair Compston's work has provided important insights into the genetics and treatment of multiple sclerosis.
New research has found that people who consume relatively high amounts of flavonols have a lower risk of stroke. Tea was most likely the major contributor of flavonols in the diet, ranging from 30 percent (US) to 70 percent (the Netherlands) of the total intake.
In the heart of California's leading healthcare provider, Kaiser Permanente, an increasing number of security officers report they either don't have health insurance or can't afford the plan for their families.
Intellipharmaceutics International Inc., today announced that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for approval to market a generic of the 30 mg strength of Focalin XR® (dexmethylphenidate hydrochloride). The application for the 30 mg strength is filed as an amendment to the ANDA that Intellipharmaceutics had previously filed for the 5, 10, 15 and 20 mg strengths of the drug.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the issuance of U.S. Patent Nos. 7,615,353, which issued in November 2009, and 7,736,861, which issued yesterday.
› Verified 8 days ago